Radiotherapy in the treatment of extracranial hemangiopericytoma/solitary fibrous tumor: Study from the Rare Cancer Network.

Autor: Krengli M; Dept. of Radiation Oncology, University Hospital, Novara, Italy; Dept. of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: marco.krengli@med.uniupo.it., Cena T; Dept. of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Zilli T; Dept. of Radiation Oncology, Geneva University Hospital, Switzerland., Jereczek-Fossa BA; Dept. of Oncology and Hemato-Oncology of University of Milan, Italy; Dept. of Radiation Oncology of European Institute of Oncology IRCCS, Milan, Italy., De Bari B; Dept. of Radiation Oncology, University Hospital 'Jean Minjoz', Besançon, France; Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne (UniL), Lausanne, Switzerland., Villa Freixa S; Catalan Institute of Oncology, Badalona, Spain; Institut Oncologic Teknon, Universitat Autònoma de Barcelona, Spain., Kaanders JHAM; Dept. of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Torrente S; Dept. of Radiation Oncology, University Hospital, Novara, Italy., Pasquier D; Dept. of Radiation Oncology, Centre O. Lambret, Lille, France., Sole CV; Dept. of Radiation Oncology, Clinica Instituto de Radiomedicina, Santiago, Chile; Faculty of Medicina, Universidad Diego Portales, Santiago, Chile., Lutsyk M; Dept. of Radiation Oncology, Rambam Medical Center, Haifa, Israel., Dincbas FO; Dept. of Radiation Oncology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Turkey., Habboush Y; Dept. of Radiation Oncology, Mayo Clinic, Jacksonville, USA., Fariselli L; Radiotherapy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta Milan, Italy., Dragan T; Dept. of Radiation Oncology, Institut J.Bordet, Brussels, Belgium., Baumert BG; Dept. of Radiation-Oncology of MediClin Robert-Janker-Clinic, Bonn, Germany; Dept. of Radiology, Radiation-Oncology, University Hospital, Bonn, Germany., Khanfir K; Dept. of Radiation Oncology, Centre Hospitalier du Valais Romand, Sion, Switzerland., Ugurluer G; Dept. of Radiation Oncology, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey., Thariat J; Dept. Of Radiation Oncology, Centre A. Lacassagne, Nice, France; Dept. of Radiation Oncology, Centre F. Baclesse, Caen, France.
Jazyk: angličtina
Zdroj: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2020 Mar; Vol. 144, pp. 114-120. Date of Electronic Publication: 2019 Dec 02.
DOI: 10.1016/j.radonc.2019.11.011
Abstrakt: Background and Purpose: The role of radiotherapy (RT) in the treatment of hemangiopericytoma/solitary fibrous tumor (HPC/SFT) is still under debate. We aimed at investigating whether radiotherapy can improve the results in patients operated for extracranial HPC/SFT.
Materials and Methods: Data from patients with HPC/SFT, treated from 1982 to 2012, were retrospectively reviewed within the Rare Cancer Network framework. Actuarial local control (LC), disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) were calculated with Kaplan-Meyer method. Patient and tumor parameters were analyzed by univariate and multivariate analysis.
Results: Of 114 HPC/SFT, 58 (50.9%) occurred in the extremities/superficial trunk and 56 (49.1%) in intra-thoracic/retroperitoneum. Seventy-eight patients (68.4%) underwent surgery only (Sx), and 36 (31.6%) Sx and RT (Sx + RT). Median RT dose was 60 Gy (range 45-68.4 Gy) in 1.6-2.2 Gy fractions. In the extremities/superficial trunk group of patients, actuarial 5-year LC rates were 50.4% after Sx and 91.6% after Sx + RT (p < 0.0001) for LC, and 50.4% after Sx and 83.1% after Sx + RT (p = 0.008) for DFS. In the intra-thoracic/retroperitoneum group of patients, actuarial 5-year rates were 89.3% after Sx and 77.8% after Sx + RT (p = 0.99) for LC, and 73.8% after Sx and 77.8% after Sx + RT (p = 0.93) for DFS. At multivariate analysis, the addition of RT resulted in better LC and DFS in the whole series. The advantage was confirmed for LC in the group of patients affected by extremity/superficial trunk tumors.
Conclusion: Addition of RT to Sx could improve the prognosis, in terms of LC and DFS, essentially in patients with extremities/superficial trunk tumor locations.
(Copyright © 2019 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: